Procore signs multi-year strategic collaboration agreement with AWS
On April 30, 2025, Amy Ladd, a director at Intuitive Surgical Inc . (NASDAQ:ISRG), a $186 billion medical technology company trading near $517 per share, executed a series of stock transactions involving the company’s common shares. According to InvestingPro analysis, ISRG currently trades at a premium to its Fair Value. Ladd sold a total of 8,776 shares at an average price of $505.55 per share, amounting to approximately $4.44 million.
In addition to the sales, Ladd acquired a total of 8,776 shares through multiple option exercises. The purchase prices for these options ranged from $171.07 to $295.92 per share, with a total transaction value of approximately $2.01 million. The company maintains excellent financial health with a GREAT overall score and strong liquidity metrics.
All transactions were conducted under a pre-established trading plan that complies with SEC Rule 10b5-1, set to expire on January 29, 2026. Following these transactions, Ladd holds 1,410 shares of Intuitive Surgical directly. Track insider transactions and access comprehensive financial analysis with InvestingPro’s detailed research reports, available for 1,400+ US stocks.
In other recent news, Intuitive Surgical has received FDA clearance for its da Vinci (EPA:SGEF) Single Port (SP) surgical system, allowing for its use in colorectal surgery, specifically for transanal local excision/resection. This development expands the system’s capabilities, which already include various urology, transoral otolaryngology, and general thoracoscopic procedures. Stifel analysts have maintained a Buy rating on Intuitive Surgical, with a price target of $670, noting strong first-quarter procedure growth as a key performance indicator. Meanwhile, RBC Capital Markets adjusted its price target to $605, maintaining an Outperform rating after the company’s earnings report exceeded expectations. Truist Securities also revised their price target to $590, retaining a Buy rating, highlighting the positive revenue and earnings per share outcomes despite tariff impacts. Piper Sandler reduced its price target to $575 while maintaining an Overweight rating, acknowledging the company’s strong earnings performance and growth potential. Intuitive Surgical has raised its 2025 procedure growth guidance from 13-16% to 15-17%, reflecting its ongoing momentum despite anticipated tariff-related challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.